Latest News

FDA Committees Vote to Dismiss Clozapine REMS
FDA Committees Vote to Dismiss Clozapine REMS

November 20th 2024

Calling it a barrier to care, FDA committees decide to end clozapine REMS.

schizophrenia brain
Beyond Dopamine: Muscarinic Solutions Bring New Hope for Schizophrenia

November 20th 2024

schizophrenia
Long-Acting Injectables and a Team-Driven Approach for Schizophrenia Treatment

November 18th 2024

trauma
Opening Pandora’s Box: The Importance of Assessing and Treating Trauma in Individuals Experiencing Psychosis

November 12th 2024

failed endpoint
Emraclidine for Schizophrenia Fails to Meet Primary Endpoints in Phase 2 EMPOWER Trials

November 11th 2024

Latest CME Events & Activities

2023 Annual Psychiatric Times™ World CME Conference

View More

5th Annual International Congress on the Future of Neurology®

View More

Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II

View More

Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies

View More

Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments

View More

'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care

View More

Real Psychiatry 2025

January 17 - 18, 2025

View More

More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression

View More

Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans

View More

Expert Perspectives in the Recognition and Management of Postpartum Depression

View More

Southern California Psychiatry Conference

July 11-12, 2025

Register Now!

SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era

View More

Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists

View More

BURST CME™ Part I: Understanding the Impact of Huntington’s Disease

View More

Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease

View More

Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea

View More

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

View More

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

View More

© 2024 MJH Life Sciences

All rights reserved.